bioSyntagma®, Inc unveiled the world’s first high-plex multi-omic spatial workflow designed for clinical samples and diagnostic applications. Compatible with FFPE and large resections up to an inch in size, the Molecular Fingerprint™ (mPrint) technology has been demonstrated to map tumor microenvironments with custom PCR panels, targeted and total sequencing, and spatial imaging at resolutions ranging from single-cell to complex regions of interest. bioSyntagma’s solution is the first to provide a pathway to diagnostic applications with its proprietary spatial-diagnostic machine learning engine that classifies tissues based on tumor microenvironment.
Read more here:
https://www.prnewswire.com/news-releases/biosyntagma-launches-first-multi-omic-spatial-platform-for-clinical-applications-301306965.html
Featured
Takara Bio USA, Inc. and bioSyntagma, Inc. Develop Method for Large-Scale Automated COVID-19 Testing
bioSyntagma, Inc, leveraged our molecular diagnostics expertise, and collaborated with Takara Bio USA, Inc., to develop and validate a new high-throughput method for detecting SARS-CoV-2 (COVID-19). The method employs automation technology and reagents from Takara BUSA to detect viral RNA via real-time PCR and will enable rapid, large-scale testing of the virus during this global pandemic.
Click here to learn more.
About bioSyntagma
bioSyntagma is a precision medicine company that enables advanced biomarker discovery and patient screening. Its suite of AI-enabled technologies enables comprehensive mapping of cancer patient biopsies (spatial, multi-omic) so that patients can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.The founders are from Arizona State University and members of the Center for Entrepreneurial Innovation.
bioSyntagma Named Finalist for Global Sustainability Award
Phoenix, Arizona: bioSyntagma has been named a finalist for the competitive Katerva Awards,which recognize disruptive innovations in global sustainability. This comes after bioSyntagma’s recent debut of their mPrint Mind™, an artificial intelligence for screening cancer patients.
“We are delighted by the new sand encouraged that such an innovative group recognizes the value of creating a sustainable healthcare system,” said David Richardson, CEO of bioSyntagma. Katerva scours the globe to identify the most promising, high-impact innovations that will make the world a better place and move society closer to the 17 Sustainable Development Goals set forth by the United Nations.
Rising costs and growing numbers of diagnostic tests on the market are a huge financial burden, especially considering that most cancer patients are developing drug resistance to their treatments. “Tackling drug resistance is a crucial step in enabling personalized medicine but also in reducing costs and democratizing access,” said Colleen Ziegler, Director of Operations at bioSyntagma. “This is why we have invested so much in AI. It will change the entire landscape.” See the full list of finalists for each sustainability category at: https://katerva.net/news/10-announcing-the-finalists-of-the-2019-katerva-awards
About bioSyntagma
bioSyntagma is a precision medicine company that enables advanced biomarker discovery and patient screening. Its suite of AI-enabled technologies enables comprehensive mapping of cancer patient biopsies (spatial, multi-omic) so that patients can be matched with relevant therapies and provided recommendations to avoid acquiring drug resistance. bioSyntagma serves the needs of clinicians, academic researchers, and drug developers to advance the implementation of precision medicine for cancer treatment.The founders are from Arizona State University and members of the Center for Entrepreneurial Innovation.